Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Deal streak continues for Alexion as Achillion’s story hits $930M high note

October 17, 2019 12:22 AM UTC
Updated on Oct 17, 2019 at 12:26 AM UTC

Alexion’s proposed takeout of Achillion would complete a 21-year journey that saw the latter evolve from an antiviral play into a complement pathway company. For Alexion, it represents the next step in its quest to build its pipeline beyond Soliris.

The takeout, announced Wednesday, would see Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) acquire Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) for $6.30 per share in cash, and give Alexion two complement inhibitors to supplement its leading position in paroxysmal nocturnal hemoglobinuria...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article